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Abstract
Pneumocystis jirovecii causes severe pneumonia (PCP) in immuno-
compromised patients. Seasonal changes of PCP incidence may
be associated with climate changes. In this ﬁrst study using multi-
ple linear regression statistics to assess monthly climatic data
and Pneumocystis, PCP incidence was positively correlated with
mean temperature, but not with rainfall or wind strength.
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Pneumocystis jirovecii pneumonia (PCP) is one of the most fre-
quent and serious opportunistic infections. However, the
modes of transmission of PCP remain unknown. Air-borne
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transmission from infected or colonized humans is the
favoured model, and environmental sources are also consid-
ered [1].
Between January 1989 and December 2006, 757 PCP
patients with pneumonia due to P. jirovecii were microscopi-
cally diagnosed, using mainly bronchoalveolar lavage specimens
at the Max-von-Pettenkofer-Institute, which serves the major
infectious disease hospitals in Munich (1.3 million inhabitants).
In order to analyse climatic effects on PCP incidence, climate
data concerning Munich [mean temperature (TMM), total pre-
cipitation representing rainfall activity (RSS), mean wind force
(FMM), maximum wind-speed (FXX)] were obtained monthly
from the German National Meteorological Service (http://
www.dwd.de). In order to analyse seasonal effects, four
groups (variables) were created: summer (May–August), win-
ter (November–February), spring (March–April) and autumn
(September–October) according to average monthly TMM.
Since climate data were available only for May 1992 to
December 2006, the 576 PCP patients (77.4% HIV-positive)
diagnosed during this period were included in a study of the
inﬂuence of climatic factors on PCP incidence. Analysis took
into consideration the pre- and post-HAART years (before
and after January 1997).
The pre-HAART mean annual PCP incidence was nearly
twice that of the post-HAART period (57.6 vs. 29.6). In May
and August PCP incidence was highest (Fig. 1). Bivariate
graphical exploration and regression modelling of the inﬂu-
ence of weather parameters on monthly incidence rates as
dependent variables, with adjustment for mean annual inci-
dence and logarithmic transformation to achieve normal dis-
tribution, were performed [SPSS version 12.0 (SPSS Inc,
Chicago, IL, USA), STATA 10.0 (StataCorp LP, College Sta-
tion, TX, USA)]. Results of the linear regression modelling
are summarized in Table 1. Fractional polynomial analysis did
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FIG. 1. PCP cases per month, on average
(Munich, May 1992 to December 2006).
Monthly PCP case numbers were adjusted for
annual case numbers (adjustment factor:
annual cases/average annual cases).
TABLE 1. Association of climatic factors with monthly PCP case numbers (Munich, May 1992 to December 2006)
Variable
Bivariate Multiple
Coeff. b 95% CI p R2 Coeff. b 95% CI p R2
TMM 0.016 0.005–0.026 0.004 0.048 )0.005 )0.023–0.012 0.551 –
RSS 0.001 )0.001–0.003 0.215 0.009 )0.001 )0.003–0.002 0.641 –
FMM )0.161 )0.389–0.067 0.166 0.011 0.062 )0.349–0.225 0.671 0.119
FXX 0.001 )0.014–0.017 0.862 <0.001 0.004 )0.014–0.023 0.665 –
HAART )0.143 )0.309–0.023 0.090 0.016 )0.130 )0.291–0.030 0.111 –
Summer 0.347 0.191–0.503 <0.001 0.099 0.415 0.154–0.676 0.002 –
Bivariate and multiple linear regression models [dependent variable: logarithmic (ln) transformation of adjusted monthly cases + 1; bold: ﬁnal model].
Variables: mean temperature 2 m above ground (TMM), total precipitation as a measurement for rainfall activity (RSS), mean wind-force (FMM); maximum wind speed at a
altitude of 10 m (strongest gust) (FXX); post-HAART vs. pre-HAART (HAART); months May through August (summer).
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not improve the model ﬁt [2]. Although no signiﬁcant corre-
lation was found between PCP incidence and RSS, FMM or
FXX, PCP incidence was positively correlated with TMM.
Interestingly, the power of the variable ‘summer’ was much
stronger than TMM in explaining PCP incidence. Additional
inclusion of any single of the four weather parameters into
the model did not have a robust effect on PCP incidence
when compared with the variable ‘summer’ alone. Whereas
PCP monthly incidence was independent of the pre- and
post-HAART periods, the ‘summer’ effect was signiﬁcantly
more pronounced in the post-HAART period. Lag modelling
considering a 4- or 8-week incubation period, based on ani-
mal and human outbreak studies [3–6], had no additional
beneﬁt in explaining PCP seasonality.
In contrast to mainly descriptive studies from Spain [7,8]
and the UK [9], which showed PCP incidence to be maximal
in the winter months, similar to the situation with other
infectious respiratory diseases, this ﬁrst study using multiple
linear regression statistics to assess monthly climatic data
and PCP incidence has revealed an opposite pattern, with
PCP incidence being maximal in the summer months. More-
over, PCP incidence was positively correlated with the mean
temperature, but not with rainfall activity or wind strength.
Most previous studies analysing seasonal variations in PCP
incidence are mainly descriptive. A seasonal distribution with
the highest PCP incidence in winter was observed in the ﬁrst
post-HAART study analysing 498 PCP patients from southern
Spain within two consecutive years [7]. These ﬁndings were
corroborated in another study from southern Spain analysing
536 PCP patients, from both the pre- and post-HAART eras
[8]. A similar pattern in 792 patients, with highest PCP inci-
dence in winter and spring, and the most pronounced peak in
January, was reported from London between 1985 and 2000
[9]. Strikingly, this seasonal pattern is opposite to that seen in
two other London-based studies [10,11]. A more hetero-
geneous incidence pattern was described in three
pre-HAART studies from the USA, the UK and Switzerland,
showing PCP peaks in the period March–June (Baltimore,
Chicago, Los Angeles, Pittsburgh, 202 AIDS patients [12]),
early summer (London, 137 HIV patients [10]) or summer
and autumn (Geneva, 93 HIV patients [13]).
In contrast to these descriptive studies, no seasonal clus-
tering of PCP episodes was found in 118 HIV patients from
Ohio, USA during the period 1986–1989 [14].
In two of these studies, which additionally reported mean
temperature and/or rainfall activity on a purely descriptive
level, no clear association between climate factors and PCP
incidence could be identiﬁed [10,13], while Lubis et al. [9]
found the lowest rainfall activity in the month with the high-
est PCP incidence. So far, only one study has explored the
relationship between PCP incidence and climatic factors
using statistical methods, reporting an inverse correlation
between PCP incidence and the mean temperature for
southern Spain, but without inﬂuence of relative humidity on
the number of PCP patients [8].
In comparison with these previous studies, the current
study is based on a statistically more comprehensive and
powerful methodology, using four different climatic factors as
variables that may inﬂuence PCP incidence. In contrast to the
studies from the UK and Spain, a clear positive correlation
was found between PCP incidence and the mean monthly
temperature, whereas rainfall and wind strength were not
found to be correlated with PCP incidence. Therefore, these
results do not support the concept of increased incidence of
Pneumocystis infection during colder months, as is the case
with other respiratory pathogens [8]. Also, the idea that prior
upper respiratory infections might increase susceptibility to
P. jirovecii [7,12] is not supported by our time lag analysis.
Strikingly, the inﬂuence of temperature on PCP incidence
was by far exceeded by the seasonal effect of the variable
‘summer’ (TMM 14.2 ± 1.2–18.6 ± 1.7) . A possible explana-
tion for the stronger inﬂuence of season, compared with that
of single climate parameters, might be that season-dependent
factors besides climate, such as human behaviour or type of
leisure activity, might be relevant for Pneumocystis transmission.
In conclusion, this study and others indicate that seasonal
variations in PCP incidence exist, albeit to different
extents and with different tendencies. Among the analysed
climatic parameters, TMM is the most strongly correlated
factor—again to different extents and with different tenden-
cies. However, other factors may better explain seasonal
variations in PCP incidence. The controversial data from two
London-based studies [9,10], i.e. the clustering of different
P. jirovecii genotypes according to patients’ locale in London
[11,15], and the presence or absence of an association
between certain P. jirovecii genotypes and climatic factors
[16], suggest that local parameters may also be important.
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